Impact of immunosuppressants on SARS-CoV-2 infection in elderly patients with inflammatory bowel disease.

Background: Older age has been reported as a risk factor for severe SARS-CoV-2 disease (COVID-19). The impact of immunosuppressants (IMS) on COVID-19 is still under debate.
Aim: To describe the incidence and severity of COVID-19 in elderly patients with inflammatory bowel disease (IBD) in relation to the use of IMS.
Methods: IBD patients over 65 years of age were selected and grouped in terms of IMS use. Confirmed COVID-19, adherence to IST, comorbidities and concomitant non-IBD-related treatments between 1st of March 2020 to 1st of March 2021 were recorded.
Results: Out of 418 patients included, 89 (21.3%) were on IMS. Thirty-two patients (7.7%) had COVID-19, 7 of whom were on IMS (7.6% not on IMS vs. 7.9% on IMS; P = 0.933) and 7 (22%) patients died.
Conclusions: Incidence of COVID-19 among elderly IBD patients was similar to that reported in the background population, regardless of the use of IMS.
(© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)